Marshall Wace’s Trevi Therapeutics TRVI Stock Holding History

Marshall Wace’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49.9M	Sell	2,674,137 -1,291,882	-33%	-$18.8M	0.04%	384
2026 Q1	$47.3M	Sell	3,966,019 -614,529	-13%	-$6.88M	0.05%	382
2025 Q4	$57.3M	Sell	4,580,548 -261,203	-5%	-$3.02M	0.05%	315
2025 Q3	$44.3M	Buy	4,841,751 +2,363,835	+95%	+$17.7M	0.04%	357
2025 Q2	$13.6M	Sell	2,477,916 -76,305	-3%	-$475K	0.02%	726
2025 Q1	$16.1M	Buy	2,554,221 +2,511,300	+5,851%	+$12M	0.02%	583
2024 Q4	$177K	Sell	42,921 -38,203	-47%	-$122K	﹤0.01%	2369
2024 Q3	$271K	Buy	+81,124	New	+$241K	﹤0.01%	2192
2022 Q4	–	Sell	-128,324	Closed	-$198K	–	3431
2022 Q3	$198K	Buy	+128,324	New	+$421K	﹤0.01%	3086
2022 Q2	–	Sell	-23,402	Closed	-$52K	–	3859
2022 Q1	$52K	Buy	+23,402	New	+$24.2K	﹤0.01%	3244

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Marshall Wace's TRVI Position: Q2 2026 in Review

Marshall Wace reduced its Trevi Therapeutics (TRVI) stake by 33% in Q2 2026, selling an estimated $18.8M and leaving 2,674,137 shares worth $49.9M. The position accounts for 0.04% of the portfolio, ranked #384.

Marshall Wace first reported a position in TRVI in Q1 2022 and has held it in 10 quarters since. The position peaked at $57.3M in Q4 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Marshall Wace held 2,674,137 shares of Trevi Therapeutics worth $49.9M as of Q2 2026.
Marshall Wace sold 1,291,882 Trevi Therapeutics shares in Q2 2026, an estimated $18.8M.
Trevi Therapeutics made up 0.04% of Marshall Wace's portfolio in Q2 2026, its #384 holding.
Marshall Wace first reported a position in Trevi Therapeutics in Q1 2022 and has held it in 10 quarters since.
Marshall Wace's Trevi Therapeutics position peaked at $57.3M in Q4 2025.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.